Growth Hormone Disorder: Clinical Trials

8 completed. 8 Phase 1.

By phase and status

Phase	Trials	Status
Phase 1	8	Completed 8

Follow Growth Hormone Disorder: new trials by email Literature Review of Growth Hormone Disorder trials Research Report on Growth Hormone Disorder

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function. Somapacitan - Growth Hormone Disorder, Adult Growth Hormone Deficiency	Phase 1	Completed	Novo Nordisk A/S	34	2017-08-16	2019-05-24
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function Somapacitan - Growth Hormone Disorder, Adult Growth Hormone Deficiency	Phase 1	Completed	Novo Nordisk A/S	44	2017-06-20	2020-04-17
A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency somapacitan, somatropin - Growth Hormone Disorder, Growth Hormone Deficiency in Children	Phase 1	Completed	Novo Nordisk A/S	32	2013-12-16	2020-12-24
A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency somapacitan, Norditropin NordiFlex® - Growth Hormone Disorder, Adult Growth Hormone Deficiency	Phase 1	Completed	Novo Nordisk A/S	35	2012-10-12	2020-12-24
First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects somapacitan, placebo (somapacitan) - Growth Hormone Disorder, Adult Growth Hormone Deficiency	Phase 1	Completed	Novo Nordisk A/S	105	2012-01-16	2020-12-24
Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 NNC126-0083, placebo - Growth Hormone Disorder, Healthy	Phase 1	Completed	Novo Nordisk A/S	40	2008-07-01	2017-02-08
Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx® NNC126-0083, Norditropin® SimpleXx®, placebo - Growth Hormone Disorder, Healthy	Phase 1	Completed	Novo Nordisk A/S	56	2007-08-01	2017-02-09
A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin somatropin, placebo - Growth Hormone Disorder, Adult Growth Hormone Deficiency	Phase 1	Completed	Novo Nordisk A/S	86	2000-04-06	2017-02-27

Narrower conditions

Dwarfism, Pituitary (5)

Broader conditions

Bone Diseases (5)  ·  Bone Diseases, Developmental (5)  ·  Bone Diseases, Endocrine (5)  ·  Brain Diseases (5)  ·  Central Nervous System Diseases (5)  ·  Dwarfism (5)  ·  Endocrine System Diseases (5)  ·  Hypopituitarism (5)  ·  Hypothalamic Diseases (5)  ·  Musculoskeletal Diseases (5)  ·  Nervous System Diseases (5)  ·  Pituitary Diseases (5)

Interventions

somapacitan (5)  ·  NNC0195-0092 (3)  ·  Human Growth Hormone (2)  ·  NNC126-0083 (2)  ·  Growth Hormone (1)

Sponsors

Novo Nordisk A/S (8)

Countries

Germany (3)  ·  Denmark (2)  ·  Sweden (2)  ·  Austria (1)  ·  Belgium (1)  ·  France (1)  ·  Israel (1)  ·  North Macedonia (1)  ·  Norway (1)  ·  Slovakia (1)  ·  Slovenia (1)  ·  Spain (1)  ·  Switzerland (1)  ·  United States (1)

Results publications

PMID 29671202, PMID 33754315, PMID 33864240, PMID 20427496, PMID 20718773, PMID 25013997, PMID 26727076, PMID 28656605, PMID 42369274

NIH funding

2016 (2), 2008 (1)